Rafael Meza

Rafael Meza

Auto-generated profile, based on publicly available information

Rafael Meza

Department of Epidemiology, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2014 in Annals of Internal Medicine
Verified
Journal Article
Closed access
HKHarry de Koning
Harry de Koning
RMRafael Meza
Rafael Meza
SPSylvia K. Plevritis
Sylvia K. Plevritis
KHKevin Ten Haaf
Kevin Ten Haaf
VMVidit N. Munshi
Vidit N. Munshi
PMPamela M. McMahon
Pamela M. McMahon
This comparative modeling study provides estimates of the benefits and harms of computed tomography screening for lung cancer in persons aged 45 through 90 years with various pack-year exposures to... Background: The optimum screening policy for lung cancer is unknown. Objective: To identify efficient computed tomography (CT) screening scenarios in which relatively more lung cancer deaths are av...

30 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRafael Meza
Rafael Meza
CMClare Meernik
Clare Meernik
JJJihyoun Jeon
Jihyoun Jeon
MCMichele L Cote
Michele L Cote
Lung cancer (LC) incidence in the United States (US) continues to decrease but with significant differences by histology, gender and race. Whereas squamous, large and small cell carcinoma rates have been decreasing since the mid-80s, adenocarcinoma rates remain stable in males and continue to increase in females, with large racial disparities. We analyzed LC incidence trends by histology in the US with an emphasis on gender and racial differences. LC incidence rates from 1973–2010 were obtained from the SEER cancer registry. Age-adjusted incidence trends of five major histological types by gender and race were evaluated using joinpoint regression. Trends of LC histology and stage distributions from 2005–2010 were analyzed. US LC incidence varies by histology. Squamous, large and small cell carcinoma rates continue to decrease for all gender/race combinations, whereas adenocarcinoma rates remain relatively constant in males and increasing in females. An apparent recent increase in the incidence of squamous cell carcinoma and adenocarcinoma since 2005 can be explained by a concomitant decrease in the number of cases classified as other non-small cell carcinoma. Black males continue to be disproportionally affected by squamous LCs, and blacks continue to be diagnosed with more advanced cancers than whites. LC incidence by histology continues to change over time. Additional variations are expected as screening becomes disseminated. It is important to continue to monitor LC rates to evaluate the impact of screening on current trends, assess the continuing benefits of tobacco control, and focus efforts on reducing racial disparities.

9 March 2021 in JAMA
Verified
Journal Article
Open access
PDF file
RMRafael Meza
Rafael Meza
JJJihyoun Jeon
Jihyoun Jeon
ITIakovos Toumazis
Iakovos Toumazis
KHKevin Ten Haaf
Kevin Ten Haaf
PCPianpian Cao
Pianpian Cao
CKChung Yin Kong
Chung Yin Kong
In 2013, the US Preventive Services Task Force (USPSTF) recommended annual screening for lung cancer with low-dose computed tomography (LDCT) for adults aged 55 through 80 years who have a smoking history of at least 30 pack-years and currently smoke or have quit within the past 15 years (B recommendation).1 These recommendations were largely based on the results of the National Lung Screening Trial (NLST).2-4 Since then, new clinical guidelines have emerged for classifying and managing screening-detected pulmonary nodules,5 and new evidence has emerged on the benefits and harms of LDCT screening.6,7

4 April 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
KHKevin Ten Haaf
Kevin Ten Haaf
JJJihyoun Jeon
Jihyoun Jeon
MTMartin C. Tammemägi
Martin C. Tammemägi
SHSummer S. Han
Summer S. Han
CKChung Yin Kong
Chung Yin Kong
RMRafael Meza
Rafael Meza
Selection of candidates for lung cancer screening based on individual risk has been proposed as an alternative to criteria based on age and cumulative smoking exposure (pack-years). Nine previously established risk models were assessed for their ability to identify those most likely to develop or die from lung cancer. All models considered age and various aspects of smoking exposure (smoking status, smoking duration, cigarettes per day, pack-years smoked, time since smoking cessation) as risk predictors. In addition, some models considered factors such as gender, race, ethnicity, education, body mass index, chronic obstructive pulmonary disease, emphysema, personal history of cancer, personal history of pneumonia, and family history of lung cancer. Retrospective analyses were performed on 53,452 National Lung Screening Trial (NLST) participants (1,925 lung cancer cases and 884 lung cancer deaths) and 80,672 Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) ever-smoking participants (1,463 lung cancer cases and 915 lung cancer deaths). Six-year lung cancer incidence and mortality risk predictions were assessed for (1) calibration (graphically) by comparing the agreement between the predicted and the observed risks, (2) discrimination (area under the receiver operating characteristic curve [AUC]) between individuals with and without lung cancer (death), and (3) clinical usefulness (net benefit in decision curve analysis) by identifying risk thresholds at which applying risk-based eligibility would improve lung cancer screening efficacy. To further assess performance, risk model sensitivities and specificities in the PLCO were compared to those based on the NLST eligibility criteria. Calibration was satisfactory, but discrimination ranged widely (AUCs from 0.61 to 0.81). The models outperformed the NLST eligibility criteria over a substantial range of risk thresholds in decision curve analysis, with a higher sensitivity for all models and a slightly higher specificity for some models. The PLCOm2012, Bach, and Two-Stage Clonal Expansion incidence models had the best overall performance, with AUCs >0.68 in the NLST and >0.77 in the PLCO. These three models had the highest sensitivity and specificity for predicting 6-y lung cancer incidence in the PLCO chest radiography arm, with sensitivities >79.8% and specificities >62.3%. In contrast, the NLST eligibility criteria yielded a sensitivity of 71.4% and a specificity of 62.2%. Limitations of this study include the lack of identification of optimal risk thresholds, as this requires additional information on the long-term benefits (e.g., life-years gained and mortality reduction) and harms (e.g., overdiagnosis) of risk-based screening strategies using these models. In addition, information on some predictor variables included in the risk prediction models was not available. Selection of individuals for lung cancer screening using individual risk is superior to selection criteria based on age and pack-years alone. The benefits, harms, and feasibility of implementing lung cancer screening policies based on risk prediction models should be assessed and compared with those of current recommendations.

20 November 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
JJJihyoun Jeon
Jihyoun Jeon
THTheodore R. Holford
Theodore R. Holford
DLDavid T. Levy
David T. Levy
EFEric J. Feuer
Eric J. Feuer
PCPianpian Cao
Pianpian Cao
RMRafael Meza
Rafael Meza
Tobacco control efforts implemented in the United States since the 1960s have led to considerable reductions in smoking and smoking-related diseases, including lung cancer. To project reductions in tobacco use and lung cancer mortality from 2015 to 2065 due to existing tobacco control efforts. Comparative modeling approach using 4 simulation models of the natural history of lung cancer that explicitly relate temporal smoking patterns to lung cancer rates. U.S. population, 1964 to 2065. Adults aged 30 to 84 years. Models were developed using U.S. data on smoking (1964 to 2015) and lung cancer mortality (1969 to 2010). Each model projected lung cancer mortality by smoking status under the assumption that current decreases in smoking would continue into the future (status quo trends). Sensitivity analyses examined optimistic and pessimistic scenarios. Under the assumption of continued decreases in smoking, age-adjusted lung cancer mortality was projected to decrease by 79% between 2015 and 2065. Concomitantly, and despite the expected growth, aging, and longer life expectancy of the U.S. population, the annual number of lung cancer deaths was projected to decrease from 135 000 to 50 000 (63% reduction). However, 4.4 million deaths from lung cancer are still projected to occur in the United States from 2015 to 2065, with about 20 million adults aged 30 to 84 years continuing to smoke in 2065. Projections assumed no changes to tobacco control efforts in the future and did not explicitly consider the potential effect of lung cancer screening. Tobacco control efforts implemented since the 1960s will continue to reduce lung cancer rates well into the next half-century. Additional prevention and cessation efforts will be required to sustain and expand these gains to further reduce the lung cancer burden in the United States. National Cancer Institute.

29 October 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Alicia KraayAlicia Kraay
Alicia Kraay
MHMichael A.L. Hayashi
Michael A.L. Hayashi
NHNancy Hernandez-Ceron
Nancy Hernandez-Ceron
ISIan H. Spicknall
Ian H. Spicknall
MEMarisa C. Eisenberg
Marisa C. Eisenberg
JEJoseph Eisenberg
Joseph Eisenberg
Fomite mediated transmission can be an important pathway causing significant disease transmission in number of settings such as schools, daycare centers, and long-term care facilities. The importance of these pathways relative to other transmission pathways such as direct person-person or airborne will depend on the characteristics of the particular pathogen and the venue in which transmission occurs. Here we analyze fomite mediated transmission through a comparative analysis across multiple pathogens and venues. We developed and analyzed a compartmental model that explicitly accounts for fomite transmission by including pathogen transfer between hands and surfaces. We consider two sub-types of fomite-mediated transmission: direct fomite (e.g., shedding onto fomites) and hand-fomite (e.g., shedding onto hands and then contacting fomites). We use this model to examine three pathogens with distinct environmental characteristics (influenza, rhinovirus, and norovirus) in four venue types. To parameterize the model for each pathogen we conducted a thorough literature search. Based on parameter estimates from the literature the reproductive number ( $\mathcal {R}_{0}$ ) for the fomite route for rhinovirus and norovirus is greater than 1 in nearly all venues considered, suggesting that this route can sustain transmission. For influenza, on the other hand, $\mathcal {R}_{0}$ for the fomite route is smaller suggesting many conditions in which the pathway may not sustain transmission. Additionally, the direct fomite route is more relevant than the hand-fomite route for influenza and rhinovirus, compared to norovirus. The relative importance of the hand-fomite vs. direct fomite route for norovirus is strongly dependent on the fraction of pathogens initially shed to hands. Sensitivity analysis stresses the need for accurate measurements of environmental inactivation rates, transfer efficiencies, and pathogen shedding. Fomite-mediated transmission is an important pathway for the three pathogens examined. The effectiveness of environmental interventions differs significantly both by pathogen and venue. While fomite-based interventions may be able to lower $\mathcal {R}_{0}$ for fomites below 1 and interrupt transmission, rhinovirus and norovirus are so infectious ( $\mathcal {R}_{0}>>1$ ) that single environmental interventions are unlikely to interrupt fomite transmission for these pathogens.